Anlotinib in Combination with TQB2450 in Patients with Platinum-Resistant or Platinum-Refractory Ovarian Cancer (ACTION): A Multicenter, Single-Arm, Open-Label, Phase 1b Trial

SSRN Electronic Journal ◽

10.2139/ssrn.3987490 ◽

2021 ◽

Author(s):

Chunyan Lan ◽

Jing Zhao ◽

Fan Yang ◽

Ying Xiong ◽

Rong Li ◽

...

Keyword(s):

Ovarian Cancer ◽

Platinum Resistant ◽

Open Label Phase ◽

Platinum Refractory ◽

Download Full-text

Avelumab Alone or in Combination with Chemotherapy vs Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): A Randomised, Open-Label, Phase 3 Study

SSRN Electronic Journal ◽

10.2139/ssrn.3720725 ◽

2020 ◽

Author(s):

Eric Pujade-Lauraine ◽

Keiichi Fujiwara ◽

Jonathan A. Ledermann ◽

Amit M. Oza ◽

Rebecca S. Kristeleit ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase 3 ◽

Platinum Resistant ◽

Open Label Phase ◽

Platinum Refractory

Download Full-text

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(15)70115-4 ◽

2015 ◽

Vol 16 (5) ◽

pp. 561-568 ◽

Author(s):

Sandro Pignata ◽

Domenica Lorusso ◽

Giovanni Scambia ◽

Daniela Sambataro ◽

Stefano Tamberi ◽

...

Keyword(s):

Ovarian Cancer ◽

Advanced Ovarian Cancer ◽

Weekly Paclitaxel ◽

Phase 2 ◽

Phase 2 Trial ◽

Platinum Resistant ◽

Open Label Phase ◽

Platinum Refractory

Download Full-text

Apatinib, a novel VEGFR inhibitor, combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer: A single-arm, open-label, phase 2 study.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5515 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5515-5515

Author(s):

Chunyan Lan ◽

Yin Wang ◽

Ying Xiong ◽

Judong Li ◽

Yanfang Li ◽

...

Keyword(s):

Ovarian Cancer ◽

Oral Etoposide ◽

Phase 2 ◽

Platinum Resistant ◽

Phase 2 Study ◽

Open Label Phase ◽

Platinum Refractory ◽

Vegfr Inhibitor

Download Full-text

5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(07)71177-1 ◽

2007 ◽

Vol 5 (4) ◽

pp. 312 ◽

Author(s):

S. Loibl ◽

J. Pfisterer ◽

P. Wimberger ◽

C. Kurzeder ◽

A. Du Bois ◽

...

Keyword(s):

Ovarian Cancer ◽

Epithelial Ovarian Cancer ◽

Cancer Patients ◽

Bispecific Antibody ◽

Open Label Phase ◽

Platinum Refractory

Download Full-text

Anlotinib combined with pemetrexed as a further treatment of patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study

Gynecologic Oncology ◽

10.1016/s0090-8258(21)00758-7 ◽

2021 ◽

Vol 162 ◽

pp. S61-S62

Author(s):

Jueming Chen ◽

Wei Wei ◽

Lie Zheng ◽

Han Li ◽

Yanling Feng ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Platinum Resistant ◽

Open Label Phase

Download Full-text

721O Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1164 ◽

2021 ◽

Vol 32 ◽

pp. S725

Author(s):

N. Colombo ◽

D.D. Nguyen ◽

G.F. Fleming ◽

R.N. Grisham ◽

D. Lorusso ◽

...

Keyword(s):

Ovarian Cancer ◽

Glucocorticoid Receptor ◽

Phase Ii ◽

Phase Ii Study ◽

Progression Free Survival ◽

Free Survival ◽

Receptor Modulator ◽

Platinum Resistant ◽

Open Label Phase

Download Full-text

Abstract CT157: An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial

10.1158/1538-7445.am2019-ct157 ◽

2019 ◽

Author(s):

Joyce Liu ◽

Camille Gunderson ◽

Andrea Wahner Hendrickson ◽

Elena Ratner ◽

Elisabeth Diver ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Platinum Resistant ◽

Open Label Phase

Download Full-text

Abstract CT157: An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial

10.1158/1538-7445.sabcs18-ct157 ◽

2019 ◽

Author(s):

Joyce Liu ◽

Camille Gunderson ◽

Andrea Wahner Hendrickson ◽

Elena Ratner ◽

Elisabeth Diver ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Platinum Resistant ◽

Open Label Phase

Download Full-text

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(21)00216-3 ◽

2021 ◽

Author(s):

Eric Pujade-Lauraine ◽

Keiichi Fujiwara ◽

Jonathan A Ledermann ◽

Amit M Oza ◽

Rebecca Kristeleit ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase 3 ◽

Platinum Resistant ◽

Platinum Refractory

Download Full-text

732P Anlotinib plus pemetrexed in patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study

Annals of Oncology ◽

10.1016/j.annonc.2021.08.1175 ◽

2021 ◽

Vol 32 ◽

pp. S734

Author(s):

J. Chen ◽

W. Wei ◽

L. Zheng ◽

H. Li ◽

Y. Feng ◽

...

Keyword(s):

Ovarian Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Platinum Resistant ◽

Open Label Phase

Download Full-text